10x Genomics Corp (TXG): Prakiraan pendapatan perusahaan

TXG (10x) - tandha merek perusahaan

Compliance with Western export restrictions in China is hindering the expansion of 10x Genomics, Inc. (TXG) due to the sensitivity of biodata. Revenues are based on the sale of high-cost instruments and the regular sale of proprietary consumables. An innovative staff of geneticists is retained through generous RSUs. The trend in the company's sales performance helps assess commercial prospects, and 0.62 captures the current value of the indicator for future sales volume.

10x - Pendapatan mangsa ngarep perusahaan TXG (periode 04.07.2022 - 16.11.2026)

10x Genomics Corp (TXG) - rincian metrik lan laporan keuangan

Analisis fundamental perusahaan:10x Genomics Inc TXG
Produk mawa merek 10x Genomics Inc

The monopoly position of 10x Genomics, Inc. (TXG) in the field of spatial genome analysis and the expansion of Chromium systems create a steady revenue stream from the sale of high-margin reagents. The company's predictive sales model reflects the market discounting of these prospects, allowing investors to use revenue dynamics to promptly diagnose business model attrition or confirm the asset's growth potential prior to the publication of official financial reports.

Pesaing utama

Volume dodolan mangsa ngarep perusahaan TEM (Tempus AI)|Dodolan mangsa ngarep perusahaan Qiagen Group|Prakiraan pendapatan perusahaan Ionis Pharma IONS|RGEN - Volume dodolan mangsa ngarep perusahaan|RNA - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan RARE (Ultragenyx)|Volume dodolan mangsa ngarep perusahaan BEAM|Prakiraan volume dodolan Sarepta Corp|Prakiraan pendapatan perusahaan Twist Bioscience, Inc. (TWST)|Prakiraan volume dodolan intelliatx.com (NTLA)|Stoke Therapeutics - Volume dodolan mangsa ngarep perusahaan|BioLife Solutions Inc (BLFS) - Volume dodolan sing dikarepake perusahaan|wavelifesciences.com - Prakiraan volume dodolan|Maze Therapeutics Corp (MAZE) - Volume dodolan mangsa ngarep perusahaan|SION: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan PRME|Prakiraan pendapatan perusahaan Taysha Gene Therapies|Prakiraan pendapatan perusahaan QURE (uniQure)|Prakiraan pendapatan perusahaan MeiraGTx (MGTX)|REGENXBIO Corp - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Solid Biosciences SLDB|OCGN - Volume dodolan mangsa ngarep perusahaan|pacb.com - Prakiraan volume dodolan|Benitec (BNTC) - Volume dodolan mangsa ngarep perusahaan|DSGN: Prakiraan volume dodolan|RCKT - Dodolan mangsa ngarep perusahaan|FDMT: Dodolan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan LXEO (lexeotx.com)|Prakiraan pendapatan perusahaan Korro Bio Inc. (KRRO)|Prakiraan volume pendapatan perusahaan EDIT|Prakiraan volume dodolan SLN (Silence Therapeutics PLC)|Pendapatan mangsa ngarep perusahaan PRQR|CDXS - Prakiraan pendapatan perusahaan|SGMO (Sangamo Therapeutics) - Prakiraan pendapatan perusahaan|NAUT: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan MGX|DTIL (precisionbiosciences.com) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GBIO (Generation Bio Co.)|Prakiraan pendapatan perusahaan Boundless Bio (BOLD)|Exicure - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan IMNN (imunon.com)|Dodolan mangsa ngarep perusahaan Phio Pharmaceuticals (PHIO)|MBIO: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Prakiraan pendapatan perusahaan|APDN - Dodolan mangsa ngarep perusahaan|Volume dodolan mangsa ngarep perusahaan BLUE|Prakiraan volume dodolan immunoprecise.com|Prakiraan volume dodolan OMGA|Dodolan mangsa ngarep perusahaan Singular Genomics Corp|Regulus Therapeutics - Volume dodolan mangsa ngarep perusahaan|SYRS (Syros Pharmaceuticals) - Pendapatan sing dikarepake perusahaan|Telesis Bio Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan TCON (TRACON Pharmaceuticals Inc.)|UBX: Prakiraan volume dodolan